EGFR and colorectal cancer: The landscape of KRAS mutations in colorectal cancer has widened considerably: first evidences pointing out at KRAS exon 2 mutations as predictors of primary resistance to anti-EGFR therapy in mCRC (1–3) have been joined with the results of further studies that have also proved the role of other mutational hotspots (in exons 3 and 4, respectively) (4).